AXS26_DigitalGuide_Final pages - Flipbook - Page 25
First and only silencer for
ATTR-CM and hATTR-PN
1
Target TTR production with only 4 subcutaneous,
HCP-administered doses per year.1* Serum TTR
knockdown was first measured at 6 weeks in HELIOS-B
and 3 weeks in HELIOS-A.2,3
*Once every 3 months.1
TO LEARN MORE ABOUT AMVUTTRA
Scan to visit www.amvuttrahcp.com
ATTR-CM=cardiomyopathy of transthyretin-mediated amyloidosis; hATTR-PN=polyneuropathy of hereditary transthyretin-mediated
amyloidosis; HCP=healthcare professional; TTR=transthyretin.
References: 1. AMVUTTRA Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc. 2. Fontana M, Berk JL, Gillmore
JD, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med. 2025;392(1):33-44 (supplement).
3. Adams D, Tournev IL, Taylor MS, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated
amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023;30(1):18-26.
AMVUTTRA and its associated logo are trademarks of Alnylam Pharmaceuticals, Inc.
© 2026 Alnylam Pharmaceuticals, Inc. All rights reserved. AMV-USA-01572
